Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03545659
Other study ID # ALL-Relapse
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 4, 2018
Est. completion date January 20, 2021

Study information

Verified date June 2020
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Over the past decades, advances in treatment have led to an increasing number of children who survive cancer, resulting in a growing population of childhood cancer survivors. After end of cancer treatment on common protocols survivors are enrolled in non-harmonized follow-up programs with frequent visits and blood samples. However, the evidence for the value of these follow-up programs with respect to the effect on detecting relapse and the effects on overall survival is scarce. The aim of the study is to give a comprehensive description of the detection mode of relapsed acute lymphoblastic leukaemia (ALL), including symptoms and blood test results. Further, we aim to evaluate if the mode of detection affects survival.


Description:

Investigators have identified a cohort of children with B-precursor ALL and T-ALL enrolled in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92, ALL-2000 and ALL-2008 trials and experienced a relapse or an SMN as the first event after cessation of maintenance therapy (368 patients). From medical charts and blood test results it will be decided whether the relapse/SMN was diagnosed at a routine visit (including routine blood tests) or if the relapse was diagnosed because of symptoms at a non-scheduled visit or blood test. As the NOPHO database probably is one of the most complete databases globally, it is an advantage to perform this study as a NOPHO study. Results of this population based relapse study will provide an evidence-based background for planning optimal and relevant follow-up programs for children after therapy of ALL treated according to contemporary Nordic ALL protocols. The study is important and relevant in the light of today's high ALL cure rates and a need for optimal follow-up programs after cessation of ALL treatment and possible prediction of relapse. The timing of the project is an increased focus on the clinical relevance of routine clinical follow-up of patients treated for cancer.


Recruitment information / eligibility

Status Completed
Enrollment 277
Est. completion date January 20, 2021
Est. primary completion date December 30, 2020
Accepts healthy volunteers
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: - diagnosed with pre-B or T-cell ALL in the Nordic countries (Denmark, Sweden, Norway, Finland or Iceland) - included in the NOPHO ALL-92, ALL-2000 or ALL-2008 trials - treated in a Paediatric Department - developing a relapse/SMN after cessation of maintenance therapy before 31st of December 2016 Exclusion Criteria: - hematopoietic stem cell transplantation in first complete remission

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Mode of relapse/SMN detection
Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.

Locations

Country Name City State
Denmark Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital Aarhus N
Finland Department of Paediatrics and Adolescent Medicine, Turku University Hospital Turku
Iceland The National University Hospital of Iceland Reykjavík
Norway Department of Childhood Oncology, University Hospital Tromsø Tromsø
Sweden Department of Paediatric Oncology, Karolinska University Hospital Stockholm

Sponsors (1)

Lead Sponsor Collaborator
University of Aarhus

Countries where clinical trial is conducted

Denmark,  Finland,  Iceland,  Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Detection mode The proportion of relapses diagnosed at a routine visit vs. relapses diagnosed at an extra scheduled visit. Investigators will review medical charts up to three months before the diagnosis of a relapse. Relapses will be categorized to be diagnosed by either a routine visit or an extra scheduled visit.
Secondary Survival Survival, by detection mode (routine or extra visit) Time-to-Event measures (up to 23 years from date of relapse until censoring)
See also
  Status Clinical Trial Phase
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT01141335 - Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair Phase 4
Completed NCT00029185 - Study of Dehydrex in Patients With Corneal Erosion N/A
Completed NCT01351974 - Sentinel Node Biopsy in Breast Cancer Patients N/A
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Withdrawn NCT03162120 - Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation Phase 2/Phase 3
Recruiting NCT04159051 - Charité HT-Prostate N/A
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Completed NCT01989845 - Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Phase 4
Recruiting NCT01229475 - Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation N/A
Completed NCT00944554 - Relapse Prevention With Varenicline Phase 4
Terminated NCT02247258 - Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence. Phase 2
Completed NCT03654209 - Post-resection Treatment of Large Colon Polyps N/A
Recruiting NCT05557474 - Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit
Active, not recruiting NCT03865537 - Cold Snare Endoscopic Mucosal Resection Trial N/A
Completed NCT04983459 - PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer